secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001390478-24-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML
------------------------------------------------------------------------

- Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.
- Cash at Dec 31, 2023: $2.5M; subsequent $9M (Jan) and $20M (Mar 2024) raised.
- Phase 2a SLS009 in r/r AML: 50% response at 30mg BIW optimal dose; 100% in biomarker patients.
- Phase 3 REGAL (GPS) enrollment completed; IDMC meeting late April; interim analysis possible in 1H2024.
- Phase 1b/2 SLS009 in PTCL top-line data expected 1H2024; first DLBCL combo patient dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/0001390478-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/sls-20240328.htm
  HTML page:      https://secwatch.observer/filing/0001390478-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer